[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 150
81. Tsai WS, Changchien CR, Yeh CY, Chen JS, Tang R, Chiang JM, Hsieh PS, Fan CW, Wang JY: Preoperative plasma vascular endothelial growth factor but not nitrite is a useful complementary tumor marker in patients with colorectal cancer. Dis Colon Rectum; 2006 Jun;49(6):883-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Preoperative plasma vascular endothelial growth factor levels were positively correlated with tumor stage, T class, M class, and tumor size (Spearman correlation, P < 0.01), but were not associated with gender, N class, tumor location, histology type, or grade.
  • The positive rates of vascular endothelial growth factor elevation (>148.6 pg/ml) compared with carcinoembryonic antigen elevation were 36.9 to 14.6 percent in Stage I, 60.9 to 33 percent in Stage II, 62.9 to 48.7 percent in Stage III, and 86 to 70.2 percent in Stage IV, respectively.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / pathology. Colorectal Neoplasms / blood. Colorectal Neoplasms / pathology. Nitrites / blood. Vascular Endothelial Growth Factor A / blood

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16741643.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nitrites; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


82. D'Annibale A, Morpurgo E, Fiscon V, Termini B, Serventi A, Sovernigo G, Orsini C: Minimally invasive resection for colorectal cancer: perioperative and medium-term results in an unselected patient group at a single institution. Tech Coloproctol; 2006 Dec;10(4):303-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In the study period, 302 patients (mean age 66.1 years; range, 32-93 years) underwent 114 left hemicolectomies, 108 low anterior resections, 61 right hemicolectomies, 12 Miles procedures, 4 subtotal colectomies, and 3 transverse colon resections.
  • Cancer-related survival curves showed a 90% survival for stage II, 85% for stage III, and 10% for stage IV disease, 30 months after surgery.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Neoplasms / surgery. Laparoscopy. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Tech Coloproctol. 2009 Mar;13(1):103
  • (PMID = 17115319.001).
  • [ISSN] 1123-6337
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


83. Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Landmann RG, Guillem JG, Paty PB, Temple LK, Wong WD, Weiser MR: Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum; 2008 May;51(5):503-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of patients with high-risk stage II colon cancer for adjuvant therapy.
  • PURPOSE: Adjuvant therapy for Stage II colon cancer remains controversial but may be considered for patients with high-risk features.
  • The purpose of this study was to assess the prognostic significance of commonly reported clinicopathologic features of Stage II colon cancer to identify high-risk patients.
  • METHODS: We analyzed a prospectively maintained database of patients with colon cancer who underwent surgical treatment from 1990 to 2001 at a single specialty center.
  • We identified 448 patients with Stage II colon cancer who had been treated by curative resection alone, without postoperative chemotherapy.
  • Univariate and multivariate analyses identified three independent features that significantly affected disease-specific survival: tumor Stage T4 (hazard ratio (HR), 2.7; 95 percent confidence interval (CI), 1.1-6.2; P = 0.02), preoperative carcinoembryonic antigen > 5 ng/ml (HR, 2.1; 95 percent CI, 1.1-4.1; P = 0.02), and presence of lymphovascular or perineural invasion (HR, 2.1; 95 percent CI, 1-4.4; P = 0.04).
  • CONCLUSIONS: Patients with Stage II colon cancer generally have an excellent prognosis.
  • Use of commonly reported clinicopathologic features accurately stratifies Stage II colon cancer by disease-specific survival.
  • [MeSH-major] Adenocarcinoma / surgery. Colonic Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18322753.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8
Advertisement
4. Asaad SM, Jubelirer SJ, Welch CA: Prognostic indicators for stage II (Dukes' stage B) adenocarcinoma of the colon. W V Med J; 2005 Sep-Oct;101(5):210-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic indicators for stage II (Dukes' stage B) adenocarcinoma of the colon.
  • To determine the prognostic indicators that are associated with lower disease free survival (DFS) and overall survival (OS) in stage II colon cancer patients, the tumor registry records were reviewed for all patients diagnosed with stage II and III adenocarcinoma of the colon at Charleston Area Medical Center from 1986 to 1994.
  • The prognostic indicators of 174 stage II patients who had not undergone treatment were assessed for DFS and OS.
  • In addition, DFS and OS curves for stage II patients with < 7 LNR were not significantly different from survival curves for stage III patients.
  • Treatment decisions are made based primarily on stage, and stage II patients are not routinely offered adjuvant therapy.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Neoplasm Staging. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16422269.001).
  • [ISSN] 0043-3284
  • [Journal-full-title] The West Virginia medical journal
  • [ISO-abbreviation] W V Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Phelip JM, Molinié F, Delafosse P, Launoy G, Trétarre B, Bara S, Buémi A, Velten M, Danzon A, Ganry O, Bouvier AM, Grosclaude P, Faivre J: A population-based study of adjuvant chemotherapy for stage-II and -III colon cancers. Gastroenterol Clin Biol; 2010 Feb;34(2):144-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A population-based study of adjuvant chemotherapy for stage-II and -III colon cancers.
  • BACKGROUND: Although clinical trials have demonstrated that adjuvant chemotherapy improves survival for stage-III colon cancer, the benefits remain controversial for stage-II lesions.
  • The objective of the present study was to determine the extent to which adjuvant chemotherapy is used for patients with stage-II and -III colon cancers.
  • METHODS: The study population comprised 1074 patients with stage-II and -III colon cancers diagnosed in 2000 in 12 French administrative districts and recorded in population-based cancer registries.
  • RESULTS: Overall, 20.4% of patients with stage II and 61.9% with stage III received adjuvant chemotherapy.
  • Among stage-II patients, those receiving chemotherapy decreased from 57.6% in patients aged <or=50 years to 1.1% in those aged >or=85.
  • The corresponding percentages with stage III were 93.6% and 1.4%.
  • In multivariate analyses, other factors found to be independently and significantly associated with administration of adjuvant chemotherapy for stage II were extension of the cancer (stage IIA vs. stage IIB), clinical presentation (obstruction or perforation vs. uncomplicated cancer) and discussion of the case at a multidisciplinary case-review meeting.
  • For stage III, apart from age, discussion of the case at a multidisciplinary meeting was the only factor independently associated with administration of chemotherapy.
  • CONCLUSION: Adjuvant chemotherapy for stage-III colon cancer is used extensively for patients under 75 years of age.
  • On the other hand, a substantial percentage of stage-II colon cancer patients receive adjuvant chemotherapy despite its uncertain benefits.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20079591.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


86. Read TE, Fleshman JW, Caushaj PF: Sentinel lymph node mapping for adenocarcinoma of the colon does not improve staging accuracy. Dis Colon Rectum; 2005 Jan;48(1):80-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node mapping for adenocarcinoma of the colon does not improve staging accuracy.
  • PURPOSE: This study was designed to: determine the efficacy of sentinel lymph node mapping in patients with intraperitoneal colon cancer; and create an algorithm to predict potential survival benefit by using best-case estimates in favor of sentinel node mapping and lymph node ultraprocessing techniques.
  • METHODS: Forty-one patients with intraperitoneal colon cancer undergoing colectomy with curative intent were studied prospectively.
  • After mobilization of the colon and mesentery, 1 to 2 ml of isosulfan blue dye was injected subserosally around the tumor.
  • Stage of disease in the remaining 38 patients was: I, n = 10 (26 percent); II, n = 15 (39 percent); III, n = 11 (29 percent); IV, n = 2 (5 percent).
  • To create a survival benefit algorithm, we assumed the following: combined fraction of Stage I and II disease (0.5); fraction understaged by bivalving and hematoxylin and eosin staining that would have occult positive nodes by more sophisticated analysis (0.15); fraction of occult positive nodes detected by sentinel node mapping (0.9); and survival benefit from chemotherapy (0.33).
  • CONCLUSIONS: Sentinel node mapping with isosulfan blue dye and routine processing of retrieved nodes does not improve staging accuracy in patients with intraperitoneal colon cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Algorithms. Colonic Neoplasms / pathology. Neoplasm Staging / methods. Sentinel Lymph Node Biopsy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15690662.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Muc-Wierzgon M, Nowakowska-Zajdel E, Kokot T, Kozowicz A, Wiczkowski A, Grochowska-Niedworok E, Mazurek U, Wierzgon J: Genetic disregulation of TNF alpha and TNF alpha type II receptors in colon cancer at the II and III stage of disease. J Biol Regul Homeost Agents; 2006 Jan-Jun;20(1-2):10-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic disregulation of TNF alpha and TNF alpha type II receptors in colon cancer at the II and III stage of disease.
  • The expression of the genes coding TNFalpha and TNF RII receptors (TNF RII: TNFR2 membrane and soluble domain, TNFR2/R7 soluble domain) was analysed in colon cancer at the II and III stage of disease, by estimation of mRNA expression.
  • The study included 80 patients with histopathologically confirmed adenocarcinoma.
  • The highest number of mRNA TNF-alpha copies were investigated in all samples of tissue and independently of the stage of disease.
  • Simultaneously, we noticed the largest number of mRNA copies for TNFalpha and TNF R2/R7 in healthy cells at stage III of the disease.
  • [MeSH-major] Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. Gene Expression Regulation, Neoplastic / genetics. Receptors, Tumor Necrosis Factor, Type II / genetics. Tumor Necrosis Factor-alpha / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18088549.001).
  • [ISSN] 0393-974X
  • [Journal-full-title] Journal of biological regulators and homeostatic agents
  • [ISO-abbreviation] J. Biol. Regul. Homeost. Agents
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Tumor Necrosis Factor, Type II; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


88. Selvindos PB, Ho YH: Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis. Dis Colon Rectum; 2008 Nov;51(11):1710-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with adenocarcinoma underwent preoperative endorectal ultrasound to individualize for neoadjuvant chemoradiotherapy, based on local extent and lymph nodes seen.
  • The indications were adenocarcinoma (n = 51), squamous-cell carcinoma of rectum (n = 1), dermoid tumor of mesorectum (n = 1), large villous adenoma (n = 1), and carcinoid with local lymph node metastases (n = 1).
  • The histologic grading or the adenocarcinoma patients were: Stage I, n = 14; Stage II, n = 23; Stage III, n = 11; Stage IV, n = 3.
  • At a median follow-up of 14 (2-33) months, none of the adenocarcinoma patients who had undergone curative resection had recurrences.
  • Four other patients had smaller pelvic collections that resolved with antibiotics; pelvic collections were associated with advanced stage of cancer (P = 0.047).
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Colonic Pouches. Laparoscopy / methods. Proctocolectomy, Restorative / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18679748.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Interactive Tutorial
  • [Publication-country] United States
  •  go-up   go-down


89. Cai JH, Zhao R, Zhu JW, Jin XL, Wan FJ, Liu K, Ji XP, Zhu YB, Zhu ZG: Expression of cortactin correlates with a poor prognosis in patients with stages II-III colorectal adenocarcinoma. J Gastrointest Surg; 2010 Aug;14(8):1248-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cortactin correlates with a poor prognosis in patients with stages II-III colorectal adenocarcinoma.
  • BACKGROUND: The present study was designed to specifically investigate the clinicopathological role of expression of cortactin, as well as the correlation with clinical outcomes in stages II-III colorectal cancer (CRC).
  • METHODS: Two hundred and five stages II-III CRC patients were included in this study.
  • In univariate analysis, tumor invasion, American Joint Committee on Cancer (AJCC) stage, lymphovascular invasion, preoperative CEA level, and cortactin expression were significant prognostic factors for disease-free survival (P = 0.034, 0.009, 0.043, 0.004, and 0.004, respectively), while for overall survival, tumor invasion, AJCC stage, pathologic grade, preoperative CEA level, and cortactin expression were significant prognostic factors (P = 0.003, 0.008, 0.038, 0.017, and <0.001, respectively).
  • However, tumor invasion, AJCC stage, and cortactin expression influenced overall survival (P = 0.036, <0.001, and 0.004, respectively).
  • CONCLUSIONS: Cortactin may be a good biomarker to be applied in the clinical setting to predict the prognosis of patients with completely resected pathologic stages II-III CRC.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Colorectal Neoplasms / metabolism. Cortactin / biosynthesis. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neoplasma. 2008;55(2):138-42 [18237252.001]
  • [Cites] Br J Cancer. 2008 Mar 11;98(5):956-64 [18268492.001]
  • [Cites] Curr Biol. 2001 Mar 6;11(5):370-4 [11267876.001]
  • [Cites] Breast Cancer Res Treat. 2003 Apr;78(3):323-35 [12755491.001]
  • [Cites] J Histochem Cytochem. 2007 Sep;55(9):955-62 [17510372.001]
  • [Cites] Ann Surg Oncol. 2008 Dec;15(12):3433-9 [18846401.001]
  • [Cites] J Pathol. 2009 Mar;217(4):516-23 [18991334.001]
  • [Cites] Dis Colon Rectum. 2001 Feb;44(2):231-5 [11227940.001]
  • [Cites] Dis Colon Rectum. 1994 Sep;37(9):875-81 [8076486.001]
  • [Cites] Br J Cancer. 2008 Mar 11;98(5):950-5 [18268491.001]
  • [Cites] N Engl J Med. 1978 Aug 31;299(9):448-51 [683276.001]
  • [Cites] J Surg Res. 2008 Jun 1;147(1):99-107 [17655863.001]
  • [Cites] Langenbecks Arch Surg. 2000 Jul;385(4):271-5 [10958511.001]
  • [Cites] Oncol Rep. 1999 Mar-Apr;6(2):409-14 [10023012.001]
  • [Cites] Cancer. 1981 Mar 15;47(6):1424-9 [7226068.001]
  • [Cites] Cancer Invest. 2005;23(4):338-51 [16100946.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4A):1901-5 [17649792.001]
  • [Cites] Gene. 1995 Jun 14;159(1):83-96 [7607576.001]
  • [Cites] Dis Markers. 2008;25(1):17-26 [18776588.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1420-9 [15007086.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Feb;132(2):113-20 [16261345.001]
  • [Cites] Dis Esophagus. 2009;22(5):402-8 [19207554.001]
  • [Cites] Int J Oncol. 2009 Dec;35(6):1271-6 [19885549.001]
  • [Cites] Dis Colon Rectum. 2001 Dec;44(12):1791-9 [11742164.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):15-24 [9102255.001]
  • [Cites] Biochem J. 2004 Aug 15;382(Pt 1):13-25 [15186216.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):735-41 [17113340.001]
  • [Cites] J Hepatol. 2004 Oct;41(4):629-36 [15464244.001]
  • [Cites] Br J Surg. 1980 Jan;67(1):46-8 [7357243.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2795-803 [16675573.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Int J Oncol. 2008 Jul;33(1):69-79 [18575752.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer Lett. 2008 Jul 8;265(2):157-66 [18406052.001]
  • [Cites] Nat Med. 2006 Aug;12(8):875-8 [16892025.001]
  • [Cites] J Mol Diagn. 2003 Feb;5(1):48-53 [12552080.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6D):4953-5 [11326645.001]
  • [Cites] Dis Markers. 2009;26(1):9-18 [19242064.001]
  • [Cites] Cancer Res. 1986 Aug;46(8 Suppl):4244s-4248s [3524805.001]
  • [Cites] APMIS. 2009 Mar;117(3):162-75 [19245589.001]
  • [Cites] Dis Esophagus. 2008;21(5):402-8 [19125793.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5229-34 [1394126.001]
  • [Cites] Exp Cell Res. 2006 May 15;312(9):1658-70 [16527272.001]
  • (PMID = 20532661.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cortactin
  •  go-up   go-down


90. Brozovich M, Read TE, Salgado J, Akbari RP, McCormick JT, Caushaj PF: Laparoscopic colectomy for apparently benign colorectal neoplasia: A word of caution. Surg Endosc; 2008 Feb;22(2):506-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (1) a substantial fraction of patients undergoing laparoscopic colectomy for apparently benign colorectal neoplasia will have adenocarcinoma on final pathology; and (2) in our practice, we perform an adequate laparoscopic oncological resection for apparently benign polyps as evidenced by margin status and nodal retrieval.
  • Invasive adenocarcinoma was found on histological analysis of the colectomy specimen in 14 out of 63 cases (22%), standard error of the proportion 0.052.
  • Staging of the 14 cancers were I (n = 6, 43%), II (n = 3, 21%), III ( = 4, 29%), and IV (n = 1, 7%).
  • Neither dysplasia on endoscopic biopsy nor lesion diameter was predictive of adenocarcinoma.
  • Eight out of 23 (35%) patients with dysplasia on endoscopic biopsy had adenocarcinoma on final pathology versus 6/40 (15%) with no dysplasia (p = 0.114, Fisher's exact test).
  • CONCLUSION: A substantial fraction of endoscopically unresectable colorectal neoplasms with benign histology on initial biopsy will harbor invasive adenocarcinoma, some of advanced stage.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Polyps / surgery. Colorectal Neoplasms / surgery. Laparoscopy

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Am J Surg. 1999 May;177(5):384-7 [10365875.001]
  • [Cites] Ann Surg. 1979 Dec;190(6):679-83 [518167.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1341-4 [9788858.001]
  • [Cites] AORN J. 1992 Dec;56(6):1068-73 [1463326.001]
  • [Cites] Dis Colon Rectum. 2006 Jun;49(6):879-82 [16598402.001]
  • [Cites] Surg Endosc. 2005 Sep;19(9):1252-5 [16132333.001]
  • [Cites] Surg Endosc. 2007 Mar;21(3):400-3 [17180271.001]
  • [Cites] Int J Colorectal Dis. 1997;12(5):267-71 [9401839.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):505-8 [10215825.001]
  • (PMID = 17704872.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


91. Kitano S, Shiraishi N, Uyama I, Sugihara K, Tanigawa N, Japanese Laparoscopic Surgery Study Group: A multicenter study on oncologic outcome of laparoscopic gastrectomy for early cancer in Japan. Ann Surg; 2007 Jan;245(1):68-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologically, 1212 patients (93.7%) had stage IA disease, 75 (5.8%) had stage IB disease, and 7 (0.5%) had stage II disease (the UICC staging).
  • The 5-year disease-free survival rate was 99.8% for stage IA disease, 98.7% for stage IB disease, and 85.7% for stage II disease.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy / methods. Laparoscopy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):1800-8 [10430349.001]
  • [Cites] J Am Coll Surg. 1997 Apr;184(4):373-7 [9100682.001]
  • [Cites] Adv Surg. 1999;33:69-93 [10572562.001]
  • [Cites] Br J Cancer. 1996 Nov;74(10):1647-50 [8932349.001]
  • [Cites] Semin Oncol. 1996 Jun;23(3):360-8 [8658220.001]
  • [Cites] Br J Surg. 1997 Nov;84(11):1567-71 [9393281.001]
  • [Cites] J Surg Res. 1999 Jan;81(1):27-32 [9889053.001]
  • [Cites] Ann Surg. 1999 Jan;229(1):49-54 [9923799.001]
  • [Cites] Cancer. 1999 May 15;85(10):2119-23 [10326688.001]
  • [Cites] Arch Surg. 2000 Jul;135(7):806-10 [10896374.001]
  • [Cites] Dis Colon Rectum. 2001 Feb;44(2):217-22 [11227938.001]
  • [Cites] Gastric Cancer. 2001;4(2):93-7 [11706767.001]
  • [Cites] Gastric Cancer. 2001;4(2):98-102 [11706768.001]
  • [Cites] Surgery. 2002 Jan;131(1 Suppl):S306-11 [11821829.001]
  • [Cites] Surg Endosc. 2002 Mar;16(3):540-4 [11928051.001]
  • [Cites] World J Surg. 2002 Sep;26(9):1145-9 [12209244.001]
  • [Cites] J Am Coll Surg. 2003 Jan;196(1):75-81 [12517554.001]
  • [Cites] Gastric Cancer. 2003;6(1):64-8 [12673429.001]
  • [Cites] Surg Endosc. 2003 Jun;17(6):968-71 [12658427.001]
  • [Cites] J Am Coll Surg. 2003 Sep;197(3):372-8 [12946791.001]
  • [Cites] Surg Endosc. 2003 Sep;17(9):1440-4 [12820059.001]
  • [Cites] J Am Coll Surg. 2004 Jun;198(6):933-8 [15194075.001]
  • [Cites] Br J Surg. 1990 Dec;77(12):1330-4 [2276010.001]
  • [Cites] Endoscopy. 1993 Sep;25(7):445-50 [8261986.001]
  • [Cites] Surg Laparosc Endosc. 1994 Apr;4(2):146-8 [8180768.001]
  • [Cites] Surg Laparosc Endosc. 1995 Oct;5(5):359-62 [8845979.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):232-7 [15650632.001]
  • (PMID = 17197967.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1867926
  •  go-up   go-down


92. Sträter J, Herter I, Merkel G, Hinz U, Weitz J, Möller P: Expression and prognostic significance of APAF-1, caspase-8 and caspase-9 in stage II/III colon carcinoma: caspase-8 and caspase-9 is associated with poor prognosis. Int J Cancer; 2010 Aug 15;127(4):873-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and prognostic significance of APAF-1, caspase-8 and caspase-9 in stage II/III colon carcinoma: caspase-8 and caspase-9 is associated with poor prognosis.
  • To study their prognostic influence in colon carcinoma, expression of APAF-1, caspase-8 and caspase-9 was determined by immunohistochemistry in normal colon mucosa (n = 8) and R0-resected stage II/III colon carcinomas (n >or= 124) using a semiquantitative score.
  • In normal colon, APAF-1 and caspase-8 are most strongly expressed in the luminal surface epithelium, whereas caspase-9 is expressed all along the crypt axis.
  • In colon carcinomas, there is considerable variability in the expression of these proapoptotic factors, although complete loss of caspase-8 and caspase-9 is rare.
  • The influence of caspase-8 expression was mainly seen in patients with stage III colon carcinoma (p = 0.011), whereas the prognostic influence of caspase-9 expression was significant in stage II cases (p = 0.037) and just failed to be significant in stage III tumors (p = 0.0581).
  • Our data suggest that, in colon carcinomas, expression of caspase-8 and caspase-9 is significantly associated with poor survival.
  • Caspase-9 may be an independent prognosticator in colon carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Apoptotic Protease-Activating Factor 1 / metabolism. Biomarkers, Tumor / metabolism. Caspase 8 / metabolism. Caspase 9 / metabolism. Colonic Neoplasms / metabolism
  • [MeSH-minor] Aged. Colon / metabolism. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20013803.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / APAF1 protein, human; 0 / Apoptotic Protease-Activating Factor 1; 0 / Biomarkers, Tumor; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspase 9
  •  go-up   go-down


93. Wang W, Li YF, Sun XW, Chen G, Zhan YQ, Huang CY, Wan DS, Pan ZZ, Zhou ZW: Correlation analysis between loss of heterozygosity at chromosome 18q and prognosis in the stage-II colon cancer patients. Chin J Cancer; 2010 Aug;29(8):761-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation analysis between loss of heterozygosity at chromosome 18q and prognosis in the stage-II colon cancer patients.
  • In this study we detected the frequency of loss of heterozygosity (LOH) at chromosome 18q and investigated the relationship between LOH and clinicopathologic features and its prognostic value for patients with stage II colon cancer.
  • METHODS: A total of 106 samples of tumor tissues and corresponding normal mucosa from patients with sporadic stage-II colon cancer were included in this study.
  • Multivariate analysis for association between LOH and prognosis in colon cancer patients was performed with Cox proportional hazards regression model.
  • LOH was more frequent on the left-side, poorly-differentiated adenocarcinoma, and nonmucinous colon cancers.
  • The occurrence of 18q-LOH is an independent poor prognostic factor for the patients with stage-II colon cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomes, Human, Pair 18 / genetics. Colonic Neoplasms / genetics. Loss of Heterozygosity
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / genetics. Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / surgery. Adult. Age Factors. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Grading. Neoplasm Staging. Proportional Hazards Models. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Chromosome 18q-.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20663324.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


94. Papagiorgis P, Oikonomakis I, Karapanagiotou I, Wexner SD, Nikiteas N: The impact of tumor location on the histopathologic expression of colorectal cancer. J BUON; 2006 Jul-Sep;11(3):317-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Cancer of the colon and rectum has been classically viewed as the same disease entity.
  • Since tumor pathology and staging is the major determinant of the disease outcome, comparison of these parameters between right and left colon cancer is reasonably expected to contribute to a better understanding of the nature of the adenocarcinoma of the colon.
  • Patients were divided into two groups according to the location of the tumor (right or left colon) and pathology between the two groups was compared.
  • Sixty individuals had right colon cancer, while 124 subjects had left colon lesions.
  • Dukes' A (stage I) colon cancer had statistically significant higher incidence in left colon lesions (p=0.0084).
  • Conversely, Dukes' C(stage III) tumors presented more often in the right colon (p=0.029).
  • Grade III lesions showed a clear superiority for the right colon (p=0.0014), while grade II lesions were more commonly found in the left colon (p=0.0201).
  • Grade III lesions were more common in the right colon (p=0.0200) when early colonic cancers (stage 0,I and II pooled together) were compared.
  • CONCLUSION: A shift in severity towards the right colon has been documented both in terms of stage and grade.
  • [MeSH-major] Adenocarcinoma / pathology. Colon / pathology. Colorectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309156.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


95. Spisák S, Galamb B, Wichmann B, Sipos F, Galamb O, Solymosi N, Nemes B, Tulassay Z, Molnár B: [Tissue microarray (TMA) validated progression markers in colorectal cancer using antibody microarrays]. Orv Hetil; 2009 Aug 23;150(34):1607-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Surgically resected samples from ten Dukes B and six Dukes D stage patients containing both diseased and un-involved parts of the colon were freshly frozen.
  • RESULTS: The expression of 67 proteins was altered (p < 0.05) between the normal colon and cancerous samples.
  • A set of six proteins has been determined, which helps to differentiate between normal specimen, early and late stage colorectal cancer with high sensitivity and specificity.
  • [MeSH-major] Adenocarcinoma / chemistry. Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Colorectal Neoplasms / chemistry. Colorectal Neoplasms / pathology. Protein Array Analysis


96. Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, Yeatman T, Coppola D, Chen J: SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem; 2009 Jul 3;284(27):18210-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SirT1 is an inhibitor of proliferation and tumor formation in colon cancer.
  • Immunohistochemical staining revealed high level SirT1 in normal colon mucosa and benign adenomas.
  • SirT1 overexpression was observed in approximately 25% of stage I/II/III colorectal adenocarcinomas but rarely found in advanced stage IV tumors.
  • These results suggest a rationale for the use of SirT1 activators and inhibitors in the prevention and treatment of colon cancer.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Feb 17;403(6771):795-800 [10693811.001]
  • [Cites] Science. 2000 Sep 22;289(5487):2126-8 [11000115.001]
  • [Cites] Nature. 2001 Mar 8;410(6825):227-30 [11242085.001]
  • [Cites] Cell. 2001 Oct 19;107(2):137-48 [11672522.001]
  • [Cites] Cell. 2001 Oct 19;107(2):149-59 [11672523.001]
  • [Cites] Nature. 2003 Sep 11;425(6954):191-6 [12939617.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10794-9 [12960381.001]
  • [Cites] Cell. 2004 Feb 20;116(4):551-63 [14980222.001]
  • [Cites] EMBO J. 2004 Jun 16;23(12):2369-80 [15152190.001]
  • [Cites] Science. 2004 Jul 16;305(5682):390-2 [15205477.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5947-52 [7954427.001]
  • [Cites] Nature. 2005 Mar 3;434(7029):113-8 [15744310.001]
  • [Cites] Cell Metab. 2005 Jul;2(1):67-76 [16054100.001]
  • [Cites] Cell Metab. 2005 Aug;2(2):105-17 [16098828.001]
  • [Cites] Cell. 2005 Nov 4;123(3):437-48 [16269335.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10457-63 [16288037.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):28-38 [16354677.001]
  • [Cites] Oncogene. 2006 Jan 12;25(2):176-85 [16170353.001]
  • [Cites] PLoS Biol. 2006 Feb;4(2):e31 [16366736.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4368-77 [16618762.001]
  • [Cites] Nat Cell Biol. 2006 Sep;8(9):1025-31 [16892051.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8122-35 [16923962.001]
  • [Cites] Nature. 2006 Nov 16;444(7117):337-42 [17086191.001]
  • [Cites] Cell. 2006 Dec 15;127(6):1109-22 [17112576.001]
  • [Cites] Mol Cell. 2007 Feb 23;25(4):543-57 [17317627.001]
  • [Cites] Arch Dermatol Res. 2007 May;299(2):103-6 [17180656.001]
  • [Cites] Mol Cell. 2007 Jul 6;27(1):149-62 [17612497.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6612-8 [17638871.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5489-504 [17694089.001]
  • [Cites] Biochem J. 2007 Nov 1;407(3):451-60 [17620057.001]
  • [Cites] Biotechnol J. 2007 Nov;2(11):1360-8 [17806102.001]
  • [Cites] Nature. 2007 Nov 29;450(7170):712-6 [18046409.001]
  • [Cites] Mol Biol Cell. 2008 Mar;19(3):1210-9 [18184747.001]
  • [Cites] PLoS One. 2008;3(4):e2020 [18414679.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):312-23 [18835033.001]
  • (PMID = 19433578.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112215; United States / NCI NIH HHS / CA / R01 CA112215-03; United States / NCI NIH HHS / CA / CA121291; United States / NCI NIH HHS / CA / R01 CA121291; United States / NCI NIH HHS / CA / CA112215-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Small Interfering; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2709385
  •  go-up   go-down


97. Childs AJ, Burke JJ 2nd, Perry MY, Check WE, Gallup DG: Recurrent colorectal carcinoma detected by routine cervicovaginal papanicolaou smear testing. J Low Genit Tract Dis; 2005 Oct;9(4):236-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We present a case of recurrent colon cancer detected by routine, annual Papanicolaou screening.
  • CASE: A 59-year-old African American woman who had been treated for T2N0M0 (stage II, Dukes A) colon cancer 2 years before to presentation had a Pap smear showing a high-grade squamous intraepithelial lesion with a normal cervical biopsy result.
  • Because of this discrepancy, a loop electrosurgical excision procedure and endocervical curettage were performed and showed atypical glandular cells suspicious for adenocarcinoma.
  • Subsequent colonoscopy showed recurrent adenocarcinoma of the colon.
  • The patient underwent an en-block total abdominal hysterectomy and anterior-perineal resection showing invasion of recurrent colon cancer into the uterus and cervix.
  • CONCLUSION: In patients with a history of extrauterine adenocarcinoma, abnormal Pap screening may indicate recurrent or metastatic carcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colorectal Neoplasms / diagnosis. Diagnostic Tests, Routine. Neoplasm Recurrence, Local / diagnosis. Papanicolaou Test. Uterine Neoplasms / diagnosis. Vaginal Smears


98. Velenik V, Anderluh F, Oblak I, Strojan P, Zakotnik B: Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial. Croat Med J; 2006 Oct;47(5):693-700
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
  • METHODS: Between June 2004 and January 2005, 57 patients with operable, clinical stage II-III adenocarcinoma of the rectum entered the prospective phase II study.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives. Radiation-Sensitizing Agents / therapeutic use. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 2000;45(4):291-7 [10755317.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):346-53 [15913913.001]
  • [Cites] Bioorg Med Chem. 2000 Jul;8(7):1697-706 [10976516.001]
  • [Cites] Eur J Cancer. 2001 Mar;37(5):597-604 [11290435.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):675-9 [12062611.001]
  • [Cites] Lancet Oncol. 2002 Jul;3(7):415-24 [12142171.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):403-8 [12243814.001]
  • [Cites] Clin Ther. 2004 Apr;26(4):579-89 [15189755.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):110-5 [8996131.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] Dis Colon Rectum. 1997 Feb;40(2):131-9 [9075745.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5 Suppl 18):S18-8-S18-18 [9420016.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):301-8 [9440757.001]
  • [Cites] Dis Colon Rectum. 1998 May;41(5):543-9; discussion 549-51 [9593234.001]
  • [Cites] Biochem Pharmacol. 1998 Apr 1;55(7):1091-7 [9605432.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1274-81 [9849491.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):13-47 [10758303.001]
  • (PMID = 17042060.001).
  • [ISSN] 1332-8166
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Radiation-Sensitizing Agents; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2080466
  •  go-up   go-down


99. Dahl O: [Adjuvant chemotherapy for colon cancer]. Tidsskr Nor Laegeforen; 2007 Nov 29;127(23):3094-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adjuvant chemotherapy for colon cancer].
  • BACKGROUND: Radical resection is the main treatment for adenocarcinoma of the colon.
  • The background for adjuvant chemotherapy of colon cancer is presented.
  • RESULTS AND INTERPRETATION: Cure rates after curative resections of colon cancer (stage III) are improved by about 12% if patients are treated with adjuvant chemotherapy with oxaliplatin combined with 5-fluoruracil and folinat (or capecitabine) for 6 months.
  • Certain subgroups of stage II (Dukes' stage B) are also likely to benefit from adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Colonic Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18049502.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents
  • [Number-of-references] 35
  •  go-up   go-down


100. Vainer G, Vainer-Mosse E, Pikarsky A, Shenoy SM, Oberman F, Yeffet A, Singer RH, Pikarsky E, Yisraeli JK: A role for VICKZ proteins in the progression of colorectal carcinomas: regulating lamellipodia formation. J Pathol; 2008 Aug;215(4):445-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In patients, VICKZ expression varies with tumour type, with over 60% of colon, lung, and ovarian tumours showing strong expression.
  • Indeed, in stage II CRC, the level of VICKZ expression in the primary lesion correlates with the degree of lymph node metastasis.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • [Cites] J Cell Sci. 1995 Aug;108 ( Pt 8):2781-90 [7593319.001]
  • [Cites] J Cell Biol. 1994 Sep;126(5):1221-9 [8063859.001]
  • [Cites] J Cell Biol. 1997 Mar 24;136(6):1263-70 [9087442.001]
  • [Cites] Oncogene. 1997 Jun 5;14(22):2729-33 [9178771.001]
  • [Cites] Biol Cell. 1997 May;89(2):113-22 [9351191.001]
  • [Cites] Genes Dev. 1998 Jun 1;12(11):1593-8 [9620847.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1202-5 [10096548.001]
  • [Cites] J Exp Med. 1999 Apr 5;189(7):1101-10 [10190901.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):48716-24 [15355996.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8585-94 [15574765.001]
  • [Cites] Biol Cell. 2005 Jan;97(1):87-96 [15601260.001]
  • [Cites] Biol Cell. 2005 Jan;97(1):97-110 [15601261.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):188-95 [15644775.001]
  • [Cites] Science. 2005 Mar 25;307(5717):1976-8 [15731405.001]
  • [Cites] Oncologist. 2005 May;10(5):332-4 [15851791.001]
  • [Cites] J Biol Chem. 2005 May 6;280(18):18517-24 [15753088.001]
  • [Cites] J Cell Sci. 2005 Jun 1;118(Pt 11):2425-33 [15923655.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4545-52 [16002846.001]
  • [Cites] Reproduction. 2005 Aug;130(2):203-12 [16049158.001]
  • [Cites] Nature. 2005 Nov 24;438(7067):512-5 [16306994.001]
  • [Cites] EMBO J. 2006 Apr 5;25(7):1456-68 [16541107.001]
  • [Cites] Mol Biol Cell. 2006 Jun;17(6):2581-91 [16597702.001]
  • [Cites] Nature. 2006 Jun 15;441(7095):898-901 [16778892.001]
  • [Cites] Lancet Oncol. 2006 Jul;7(7):556-64 [16814207.001]
  • [Cites] Nat Neurosci. 2006 Oct;9(10):1247-56 [16980963.001]
  • [Cites] J Cell Biol. 2006 Nov 20;175(4):527-34 [17101699.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):434-42 [17255263.001]
  • [Cites] Haematologica. 2007 Feb;92(2):176-83 [17296566.001]
  • [Cites] Biochim Biophys Acta. 2007 May;1773(5):642-52 [16926057.001]
  • [Cites] Mol Cell Proteomics. 2007 May;6(5):798-811 [17289661.001]
  • [Cites] RNA. 2007 Sep;13(9):1558-69 [17652133.001]
  • [Cites] Int J Cancer. 2003 Mar 10;104(1):54-9 [12532419.001]
  • [Cites] Oncogene. 2000 Mar 16;19(12):1519-28 [10734311.001]
  • [Cites] Nature. 2000 Aug 3;406(6795):532-5 [10952316.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7045-50 [11416185.001]
  • [Cites] Oncogene. 2001 Oct 4;20(45):6544-50 [11641779.001]
  • [Cites] Gene. 2002 Apr 3;287(1-2):49-54 [11992722.001]
  • [Cites] J Cell Biol. 2003 Jan 6;160(1):77-87 [12507992.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):119-24 [12517787.001]
  • [Cites] Curr Biol. 2003 Feb 4;13(3):199-207 [12573215.001]
  • [Cites] Cell. 2003 Feb 21;112(4):453-65 [12600310.001]
  • [Cites] Br J Cancer. 2003 Mar 24;88(6):887-94 [12644826.001]
  • [Cites] Development. 2003 Dec;130(23):5649-61 [14522877.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):209-14 [14729626.001]
  • [Cites] Science. 2004 Apr 30;304(5671):743-6 [15118165.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Oct;36(10):1890-909 [15203104.001]
  • [Cites] Cell. 1986 May 9;45(3):407-15 [3698103.001]
  • [Cites] Dis Colon Rectum. 1991 Jun;34(6):458-63 [2036925.001]
  • [Cites] J Cell Biol. 1994 Sep;126(5):1211-9 [8063858.001]
  • [Cites] Mol Cell Biol. 1997 Apr;17(4):2158-65 [9121465.001]
  • (PMID = 18535985.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / R01 AR041480-13; United States / NIGMS NIH HHS / GM / R01 GM084364-17; United States / NIAMS NIH HHS / AR / R01 AR041480-11; United States / NIAMS NIH HHS / AR / AR041480-06; United States / NIAMS NIH HHS / AR / AR041480-11; United States / NIGMS NIH HHS / GM / R01 GM084364-15A1; United States / NIAMS NIH HHS / AR / R01 AR041480-10A2; United States / NIAMS NIH HHS / AR / AR041480-10A2; United States / NIAMS NIH HHS / AR / AR041480-09; United States / NIAMS NIH HHS / AR / R01 AR041480; United States / NIGMS NIH HHS / GM / R01 GM084364-18; United States / NIAMS NIH HHS / AR / R01 AR041480-09; United States / NIAMS NIH HHS / AR / AR041480-08; United States / NIAMS NIH HHS / AR / R01 AR041480-06; United States / NIAMS NIH HHS / AR / R01 AR041480-14; United States / NIGMS NIH HHS / GM / R01 GM084364-16; United States / NIAMS NIH HHS / AR / R01 AR041480-08; United States / NIAMS NIH HHS / AR / R01 AR041480-11S1; United States / NIAMS NIH HHS / AR / R01 AR041480-12; United States / NIGMS NIH HHS / GM / R01 GM084364
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / ZBP1 protein, human
  • [Other-IDs] NLM/ NIHMS314194; NLM/ PMC3148580
  •  go-up   go-down






Advertisement